Ultima-Stan 25 Mg 50 Tablets Ultima Pharma USA

Product Overview

Ultima Pharma USA’s Stan 25 mg presents stanozolol, featuring C2-C3 pyrazole substitution preventing aromatization characteristic of 17α-methylated DHT derivatives (~8-hour half-life), in USP-equivalent scored tablets for institutional catalogs. The 50-tablet tamper-evident configuration supports CIII-compliant inventory management across encrypted specialist platforms requiring batch traceability essential for DEA-regulated workflows.

U.S. domestic manufacturing eliminates customs exposure distinguishing legitimate Schedule III supply from underground tablet presses prevalent in non-verified markets. Intermediate dosage serves advanced resellers managing controlled substance inventories balancing potency and safety margins.

Ultima-Stan targets verified CIII ecosystems emphasizing commercial positioning without protocols or claims.​

Brand & Manufacturer Information

Ultima Pharma USA produces Schedule III anabolics through domestic facilities serving institutional performance distribution requiring controlled substance compliance. Stan 25 mg maintains catalog continuity alongside Ultima-Stan 50 mg and Superdrol authenticating legitimate institutional supply versus powder-converted alternatives.

Active Compound Information

Contains stanozolol (17α-methyl-2’H-5α-androst-2-enopyrazol-17β-ol), heterocyclic DHT derivative enabling high anabolic:androgenic dissociation with no estrogen conversion and moderate hepatotoxicity profile characteristic of 17α-methylated oral steroids. DEA Schedule III (21 CFR 1308.13) reflects performance dosage potential.​

25 mg strength represents balanced institutional dosing. WADA S1a prohibited globally.

Product Specifications

Quality Control & Testing Standards

25 mg stanozolol mandates USP potency assay (90-110% HPLC), dissolution profiling, and uniformity verification confirming pharmaceutical-grade content. Ultima batch documentation verifies C21H32N2O identity distinguishing legitimate production from underground alternatives.

50-tablet institutional bottling prevents diversion matching DEA protocols.

Legal & Regulatory Disclaimer

Stanozolol constitutes DEA Schedule III under 21 USC §812; non-medical handling violates Controlled Substances Act. Buyer assumes Form 222 compliance; zero medical claims provided.